Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 01, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference
November 13, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
November 09, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Tuesday, November 14, 2017 at 8:45 a.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
November 07, 2017 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
November 06, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Top-Line Results Expected by the Fourth Quarter of 2018 – – NDA Submission for LDL-C Lowering Indication for the Bempedoic Acid / Ezetimibe Combination Pill Expected by First Quarter 2019 – ANN...
Esperion to Host Analyst and Investor Day Event on October 17
October 10, 2017 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
October 02, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 –– NDA Submission for LDL-C Lowering Indication for Bempedoic Acid Planned by First Quarter 2019...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 11, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Prices Public Offering of Common Stock
August 09, 2017 21:20 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces Proposed Public Offering of Common Stock
August 08, 2017 16:31 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...